Cero Therapeutics Holdings, Inc. plans to list on the Nasdaq Capital Market under the symbol CERO. It filed a Form S-1 registration statement for an initial public offering on October 21, 2024. As of November 6, 2026, its registration is amended and on file (Form S-1, December 5, 2025).
Sell to companies like Cero Therapeutics Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
Cero Therapeutics Holdings, Inc. filed a Form S-1 registration statement for an initial public offering on 2024-10-21. It has amended it 4 times. As of its latest filing, on 2025-12-05, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
Also on the record for Cero Therapeutics Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Tibbs Isaiah | 4.63% of the class | 5%+ stakes | Source |
| March 12, 2026 | Stake report, Schedule 13G, by Tibbs Isaiah | 8.67% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
| May 6, 2025 | Form D, private offering | $5M sold | Form D page | Source |
Check before you invest in Cero Therapeutics Holdings, Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Cero Therapeutics Holdings, Inc. and the records around it.
Cero Therapeutics Holdings, Inc. elsewhere on the record
- Form D filing May 2025
Companies that share a holder
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Also filing to list on the Nasdaq Capital Market
IPO filings on the Nasdaq Capital Market in Q3 2025, newest first.
- Aureus Greenway Holdings Inc (Sep 2025)
Watch Cero Therapeutics Holdings, Inc.
Get an email when Cero Therapeutics Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cero Therapeutics Holdings, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cero Therapeutics Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cero Therapeutics Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
What the filings say
Listing
Our Common Stock is listed on Nasdaq Capital Market under the symbol “CERO.” On July 18, 2025, the last quoted sale price for the shares of our Common Stock as reported on the Nasdaq Capital Market was $8.73 per share.From the S-1 filed 2025-07-21
Shares offered
We are offering up to 4,000,000 shares of our common stock, par value $0.0001 per share (“Common Stock”), together with 4,000,000 new common warrants (the “Offered Common Warrants”) to purchase up to an aggregate of 4,000,000 shares of our Common Stock and an aggregate of 4,000,000 shares of our Common Stock issuable upon exercise of the Offered Common Warrants.From the S-1/A filed 2025-02-05
Use of proceeds
While we expect to use the net proceeds from this offering as set forth in “ Use of Proceeds ,” we are not obligated to do so.From the S-1 filed 2025-12-05
Net loss or income
We incurred net losses of approximately $8.3 million and $7.3 million for the years ended December 31, 2024 and 2023, respectively, and for the nine months ended September 30, 2025, we incurred a net loss of $15.4 million.From the S-1 filed 2025-12-05
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-10-21 | Registration statement filed | S-1 |
| 2024-10-22 | Registration statement amended | S-1/A |
| 2024-11-25 | Registration statement amended | S-1/A |
| 2024-11-27 | Registration statement filed | S-1 |
| 2024-12-23 | Registration statement filed | S-1 |
| 2025-01-21 | Registration statement amended | S-1/A |
| 2025-02-05 | Registration statement amended | S-1/A |
| 2025-07-21 | Registration statement filed | S-1 |
| 2025-12-05 | Registration statement filed | S-1 |
Tools for this story
Each opens in a new tab, filled in for Cero Therapeutics Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.